Strattera Treatment in Children With ADHD Who Have Poor Response to Stimulant Therapy
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This will be a 6-week, unblinded study using the medication Strattera for children and
adolescents with attention deficit hyperactivity disorder (ADHD) who failed to respond to an
adequate trial of stimulant treatment. Specific hypotheses are as follows:
Hypothesis 1: ADHD symptomatology in youth with ADHD will be responsive to Strattera
treatment in the short term.
Hypothesis 2: Strattera treatment (in doses of up to 120 mg/day or 1.2 mg/kg/day) in children
and adolescents with ADHD will be safe and well tolerated.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride Central Nervous System Stimulants